Last Updated on December 31, 2023 by The Health Master
Bengaluru: Eli Lilly and Co said the US Food and Drug Administration (USFDA) approved its drug for the treatment of a rare form of blood cancer. The wholesale cost of the treatment, Jaypirca, will be $21,000 per 30 days for the 200 mg dose, the U.S. drugmaker told.
The USFDA’s accelerated approval for Jaypirca marks the first of the five treatments the U.S. drugmaker hopes to launch this year, including one for obesity.
The drug, which is expected to be available in the United States in the coming weeks, aims to treat adults with mantle cell lymphoma after at least two lines of therapy.
Mantle cell lymphoma is a rare type of blood cancer that starts in white blood cells in the lymph nodes and aggressively spreads to other parts of the body.
Jaypirca’s approval is based on data from a subset of 120 patients in an early-to-mid stage trial that showed half of them responded to the drug, while 13% achieved a complete response.
The trial assessed the efficacy of 200 mg dose of the drug until disease progression or unacceptable toxicity.
Shares of Lilly were down 1.28% to $343.54 in afternoon trading.
The USFDA last week had rejected an accelerated approval of Lilly’s experimental Alzheimer’s drug donanemab because the company had not submitted enough trial data from patients who were treated for at least a year.
USFDA gives approval for Amphetamine capsules
USFDA gives tentative approval Acalabrutinib capsules, 100 mg
USFDA gives tentative approval for Dolutegravir and Rilpivirine tablets
USFDA gives tentative approval for Levomilnacipran extended-release capsules
USFDA gives approval for Febuxostat tablets
USFDA gives approval for Prasugrel tablets
USFDA issues zero observations for Gland Pharma API Facility
USFDA issues Form 483 with 9 observations to Indoco Remedies, Goa
USFDA issues Form 483 with 8 observations to Jubilant
USFDA issues Form 483 with 8 observations to Lupin
USFDA issues Form 483 with 10 observations to Aurobindo Pharma
USFDA issues Form 483 with 3 Observations to Alkem
USFDA issues zero observations for Gland Pharma API Facility
Maha FDA: Action on illegal sale of drugs misused for body building
Drug: Recall: 10,052 bottles of Levofloxacin tablets recalled due to this reason
CDCSO Panel gives nod to market for Ocrelizumab
Area required for manufacturing of Drugs, Cosmetics, Homoeopathic & Blood Centre
Drug recall: Bharat Biotech voluntarily recalls ChiroRaba vaccine due to this…
PCI should add vaccination subject in pharmacy syllabus
Medical device: Industry seeks clarity on misbranded and adulterated devices
BA / BE Studies: Bioavailability & Bioequivalence
Latest Notifications regarding Pharmaceuticals
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos by The Health Master, click on the below YouTube icon:
For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos on consumer awareness, click on the below YouTube icon:
